Please login to the form below

Not currently logged in
Email:
Password:

CGRP inhibitors

This page shows the latest CGRP inhibitors news and features for those working in and with pharma, biotech and healthcare.

AbbVie CEO Gonzalez defends Allergan takeover

AbbVie CEO Gonzalez defends Allergan takeover

For AbbVie, Allergan’s most interesting programmes are a clutch central nervous system (CNS) candidates including antidepressant Vraylar (cariprazine) – which it says has blockbuster potential – as well as oral CGRP inhibitors

Latest news

  • Orphan drugs dominate FDA's record-breaking year Orphan drugs dominate FDA's record-breaking year

    There were also a number of drugs with brand new mechanisms of action, including three CGRP inhibitors for migraine prevention from Amgen, Teva and Eli Lilly – as well as Agios

  • Amgen CEO says Aimovig is “one of most successful launches” Amgen CEO says Aimovig is “one of most successful launches”

    The company estimates that more than 100, 000 patients have taken the Novartis-partnered CGRP inhibitor since its launch in May as a once-monthly, self-injected preventive treatment for migraines. ... The strong take-up has come despite approvals for

  • Teva wins FDA OK for crucial migraine drug Teva wins FDA OK for crucial migraine drug

    analysts to predict buoyant sales of the CGRP inhibitors. ... the injectable CGRP inhibitors.

  • CGRP migraine drugs need prior approval for use, recommends ICER CGRP migraine drugs need prior approval for use, recommends ICER

    Suggests clinicians should confirm that patients have tried other therapies prior to using CGRP inhibitors. ... The Institute for Clinical and Economic Review (ICER) is recommending that insurers introduce “evidence-based prior authorisation

  • The year of the blockbuster The year of the blockbuster

    Drugs to watch in 2018. Aimovig (erenumab) from Amgen and Novartis:Migraine prevention is about to undergo a transformation with several novel calcitonin gene-related peptide (CGRP) receptor inhibitors likely gaining ... from two similar drugs targeting

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics